What is RS Research’s pipeline focused on?

RS Research’s pipeline is focused on targeted oncology programs built on the company’s Sagitta^® drug-delivery platforms. The public pipeline includes candidates of targeted chemotherapeutics and theranostics (radiodiagnostic and radiotherapeutic) for solid tumors.

Which pipeline categories does RS Research disclose publicly?

RS Research publicly discloses two main pipeline categories: targeted chemotherapeutics and theranostics. The targeted chemotherapy section lists RS-0139, RS-0337, RS-0461, RS-0625 and RS-0735, while the theranostics section lists RS-0826, RS-0964 and RS-1047.

What is RS-0139?

RS-0139 is RS Research’s lead investigational candidate, developed with Sagitta^® Bir to selectively deliver docetaxel to tumor tissue in patients with solid tumors.

What clinical milestone has RS-0139 achieved?

RS-0139 has completed a multicenter, open-label, two-step Phase 1a/1b clinical trial in patients with recurrent, locally advanced or metastatic solid tumors (NCT04261413). The completed program included dose-escalation and dose-expansion stages.

What did the Phase 1 trial of RS-0139 evaluate?

The Phase 1 study was designed to determine the optimal dose and characterize the pharmacokinetic, safety and tolerability profile of RS-0139 in patients with recurrent, locally advanced or metastatic solid tumors.

What public findings have been disclosed from RS-0139 Phase 1?

Publicly disclosed topline findings from the completed Phase 1 trial include markedly improved hematologic safety compared with conventional chemotherapy, an encouraging overall safety and tolerability profile and promising early signals of antitumor activity.

What public Phase 1 data have been presented for RS-0139?

At ASCO 2025, RS Research presented Phase 1a dose-escalation results for RS-0139 in advanced solid tumors. The public abstract reported eight patients across three dose levels, no grade 3 or higher toxicities at 60 mg/m², and pharmacokinetic findings including an approximately 4-fold longer half-life compared with docetaxel.

What is the next planned development step for RS-0139?

RS Research is preparing RS-0139 for international clinical expansion, including a Phase 2 program expected to start in Q1 2027. The company has also stated that more detailed trial data will be presented at upcoming conferences.

How does Sagitta^® relate to the pipeline?

RS Research’s pipeline candidates are designed using Sagitta^® drug-delivery platforms. Sagitta^® is a family of drug-delivery platforms designed to deliver cytotoxic and antiangiogenic payloads and radionuclides to tumor tissue.

Does RS Research’s pipeline include only chemotherapy candidates?

No. RS Research’s public pipeline includes candidates of targeted chemotherapeutics and theranostics. The company’s technology can address targeting needs in multiple indications, including non-oncology disease areas.

Are RS Research’s pipeline candidates approved medicines?

No. RS Research develops investigational programs. The website content is for general informational purposes only, does not provide medical advice and relates to products that are not approved for general use.

Where can public clinical information about RS-0139 be found?

Public information about RS-0139 is available at the ClinicalTrials.gov record NCT04261413, the ASCO 2025 Phase 1a abstract, RS Research’s May 2026 announcement of Phase 1 completion and our latest announcements. For further information, we will be happy to connect: info@rsresearch.net